Read the full stored bill text
UNOFFICIAL COPY 26 RS BR 1855
Page 1 of 2
XXXX 1/20/2026 7:57 AM Jacketed
A RESOLUTION celebrating the University of Kentucky Markey Cancer Center's 1
remarkable scientific achievements. 2
WHEREAS, the University of Kentucky Markey Cancer Ce nter treated the first 3
person in the United States with a new immunotherapy for small cell lung cancer, 4
offering hope for patients whose cancers have stopped responding to other treatments; 5
and 6
WHEREAS, Markey Cancer Center is the first site in the country to open a clinical 7
trial for ZG006 (Alveltamig), an experimental drug that works by connecting disease -8
fighting T cells to cancer cells, allowing the body's immune system to attack the cancer; 9
and 10
WHEREAS, the clinical trial addresses an unmet need for pa tients with small cell 11
lung cancer, which is often diagnosed in advanced stages; and 12
WHEREAS, immunotherapies like ZG006 represent a new treatment approach 13
when standard therapies fail; and 14
WHEREAS, the first patient was treated in October 2025, under the direction of 15
Markey Cancer Center medical oncologist Zhonglin Hao, M.D., Ph.D., who is the lead 16
investigator for the trial, co -director of Markey's Thoracic Oncology Program, and 17
medical director of Markey's Clinical Research Office; and 18
WHEREAS, the first patient treated at Markey Cancer Center experienced no side 19
effects from the initial dose, and returned two weeks later for a second treatment, which 20
was also well tolerated; and 21
WHEREAS, this immunotherapy may be effective in treating brain metastasis, 22
which is common in small cell lung cancer and typically requires whole -brain radiation; 23
and 24
WHEREAS, by helping to provide better control of this systemic disease, 25
immunotherapy may reduce or eliminate the need for brain radiation therapy, which can 26
cause cognitive problems and other side effects including fatigue and hair loss; and 27
UNOFFICIAL COPY 26 RS BR 1855
Page 2 of 2
XXXX 1/20/2026 7:57 AM Jacketed
WHEREAS, Markey Cancer Center's selection as the first United States site for a 1
trial of ZG006 stems from its status as one of 57 National Cancer Institute -designated 2
Comprehensive Cancer Centers in the nation; and 3
WHEREAS, this designation allows Markey Cancer Center to offer patients access 4
to state of the art clinical trials that test the newest treatments before they become widely 5
available; 6
NOW, THEREFORE, 7
Be it resolved by the Senate of the General Assembly of the Commonwealth of 8
Kentucky: 9
Section 1. The Senate hereby celebrates the University of Kentucky Markey 10
Cancer Center for its remarkable scientific achievements. 11
Section 2. The Clerk of the Senate is directed to transmit a copy of this 12
Resolution to Senator Reginald L. Thomas for delivery. 13